A four-amino-acid peptide from a single St Petersburg laboratory, sold as an anti-ageing telomerase activator on the strength of a three-page cell culture paper, a mouse study that found no change in average lifespan, and a human trial of a different substance.

Summary

Epitalon is the synthetic tetrapeptide Ala-Glu-Asp-Gly, designed by Vladimir Khavinson's group at the St Petersburg Institute of Bioregulation and Gerontology as a synthetic stand-in for epithalamin, a bovine pineal gland extract the same group had studied since the 1980s.1
In cultured human fetal fibroblasts it induced telomerase expression and telomere elongation, in a 2003 report of under three pages.2
In the definitive mouse lifespan study, monthly injections from age three months to death "did not influence food consumption, body weight or mean life span," but extended the lifespan of the last 10 percent of survivors by 13 percent and reduced leukaemia.1
The widely cited 12-year human study, reporting 28 percent lower mortality in elderly cardiac patients, used epithalamin, the gland extract, not epitalon.3
No study has evaluated epitalon for insomnia, the use it was nominated for, or by subcutaneous injection, the route it is sold for. The FDA found "no clinical data to support the safety of epitalon."4
The FDA raised a mechanistic concern that "continuous, chronic exposure to epitalon could enable cells to evade senescence and become cancerous," because long telomeres are associated with increased cancer risk.4 5
On 24 July 2026 the FDA's advisory committee nonetheless voted 7 to 4, with one abstention, to recommend it for compounding for insomnia. The FDA has not acted.6
Two-thirds of the 164 indexed papers carry Khavinson or Anisimov as an author. There are no registered trials.

The Most Common Error About This Compound

Attributing the epithalamin results to epitalon. The human data that product pages cite, including the 12-year mortality study, come from epithalamin, a polypeptide extract of calf pineal glands whose composition is not fully defined.3 Epitalon is a four-residue synthetic designed to imitate it. That they share a name and a laboratory does not make them the same substance, and the extract's trials, whatever their quality, are not evidence for the tetrapeptide.

Identity

What Is Epitalon?

A tetrapeptide, alanine-glutamate-aspartate-glycine, sometimes written AEDG and sold as epitalon, epithalon or epithalone. It emerged from a decades-long Russian programme on "peptide bioregulators," short peptides derived from or modelled on tissue extracts and proposed to restore the function of the tissue they came from. Epithalamin was the pineal extract; epitalon was constructed as its synthetic analogue.1

The proposed mechanisms are two. In old rhesus monkeys, ten days of intramuscular epitalon raised evening melatonin and lowered evening cortisol, which is the basis for the sleep claims.4 And in telomerase-negative human fetal fibroblasts, adding epitalon induced expression of the telomerase catalytic subunit, telomerase activity and telomere elongation, which is the basis for the anti-ageing claims.2

Who Has Studied It?

Mostly one group. Khavinson and Anisimov, with colleagues in St Petersburg and Kyiv, are authors on roughly two-thirds of the indexed literature, much of it in Bulletin of Experimental Biology and Medicine, a Russian journal published in translation. The telomerase paper is two and a half pages with no independent replication in the 23 years since. That is not a comment on its honesty. It is a description of an evidence base with one source.

Evidence Base

What Do the Mouse Studies Show?

The largest and best is the 2003 lifespan study: 54 female outbred mice per group, injected subcutaneously on five consecutive days each month from three months of age until natural death. Epitalon "did not influence food consumption, body weight or mean life span." It slowed the age-related loss of oestrous cycling, reduced chromosome aberrations in bone marrow by 17 percent, increased the lifespan of the longest-lived 10 percent by 13.3 percent and maximum lifespan by 12.3 percent, did not change total spontaneous tumour incidence, and reduced leukaemia six-fold.1

That is a real result and a modest one. The average mouse lived no longer. In transgenic HER-2/neu mice prone to breast cancer, epitalon slowed ageing markers and suppressed adenocarcinoma development; in one-year-old C3H mice it reduced malignant tumours and metastases.7 8 Every one of those studies is from the same group.

What Human Evidence Exists?

For epitalon, one study, and it is not a sleep study. Seventy-five women aged 40 to 50 working night shifts were divided by their urinary melatonin metabolite levels; the 40 with reduced levels received sublingual epitalon or placebo spray twice daily for 20 days, and melatonin metabolite excretion and clock gene expression were measured. The FDA's description: small, short, unclear whether blinded, and reporting no safety data.4 No study has evaluated epitalon in anyone with insomnia, and none has used the subcutaneous route.

For epithalamin, the extract, the same group reported a 12-year randomised study in elderly patients with coronary disease, with all-cause mortality 28 percent lower and cardiovascular mortality halved in the treated group, and a 15-year follow-up of a related pituitary peptide.3 Those are striking claims for a four-page paper, and they concern a different substance.

What Did the FDA Conclude?

"There is a lack of evidence to support the effectiveness of epitalon for the proposed use of insomnia." The available clinical information "discusses effects of epitalon on melatonin metabolite levels," but the agency "did not identify studies evaluating the use of these substances in patients with insomnia," and the therapeutic meaning of a change in melatonin metabolites "is unclear without a corresponding evaluation of clinical outcomes."4

Safety

What Is Known?

From humans, nothing. The FDA found no clinical study assessing epitalon's safety, no adverse event reports, and a single sublingual study that did not report safety data.4 From mice, chronic low-dose injection for the animals' lifetime produced no toxic effect and no increase in tumours, and epitalon was non-genotoxic in bone marrow assays.1

The Telomerase Question

This is where the compound's selling point and its safety question are the same fact.

Telomerase activation and telomere lengthening are what the marketing promises. They are also the mechanism cancers use to become immortal. The FDA's nonclinical conclusion was that epitalon-induced telomere lengthening "raises concerns that continuous, chronic exposure to epitalon could enable cells to evade senescence and become cancerous," citing the finding that long telomeres are associated with increased risk of malignant tumours, and noting that "the carcinogenic potential of continuous treatment with epitalon is unknown."4 5

The mouse data cut the other way, with reduced tumours in three studies.1 8 Mice have long telomeres and abundant telomerase already, which is one reason mouse cancer biology is a poor model for human telomere biology. Whether the concern or the reassurance applies to people who inject a telomerase activator for years is a question no one has the data to answer.

A person buying epitalon for its effect on telomeres should know that the regulator's stated safety concern is its effect on telomeres.

Regulatory Status

Is It Approved Anywhere?

No. Epitalon has no marketing authorisation, no monograph, and is not a component of any approved drug.4 It is not named on the WADA Prohibited List; as an unapproved substance it may fall under S0, and a tested athlete should ask their anti-doping organisation.

What Happened in July 2026?

In September 2023 the FDA placed epitalon in Category 2 of its interim compounding policy, and as of April 2026 it appears among substances nominated but withdrawn.9

On 24 July 2026 the Pharmacy Compounding Advisory Committee considered epitalon free base and acetate for the 503A bulks list for insomnia, proposed as subcutaneous injections at 10 mg/mL and 3 mg/mL. The FDA proposed against inclusion on every criterion: not well characterised, no information on historical compounding use, no safety data in humans plus the immunogenicity and telomere concerns, and no evidence of effectiveness for a condition with approved treatments.4 The committee voted 7 to 4, with one abstention, to recommend inclusion.6

The recommendation is advisory. As of this page's verification date the FDA has not added epitalon to the bulks list, and no pharmacy in the United States has a lawful basis on which to compound it. The FDA's review also recorded that a compounding pharmacy and its owner were sentenced for unlawful distribution of compounded drugs including epitalon, and that wellness clinics and concierge practices offer it "as an 'anti-aging' agent."4

Related ONPEPS Coverage

What Would Change This Page

Independent replication of the telomerase finding by a laboratory unconnected to the originating group, which after 23 years would be the first. A controlled human study of epitalon, by injection, measuring any clinical outcome. The FDA's decision on the July 2026 recommendation. None is registered or announced.

References

Anisimov VN, Khavinson VKh, Popovich IG, Zabezhinski MA, Alimova IN, Rosenfeld SV, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202. Paywalled. pubmed.ncbi.nlm.nih.gov/14501183
Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. Paywalled. pubmed.ncbi.nlm.nih.gov/12937682
Korkushko OV, Khavinson VKh, Shatilo VB, Antonyuk-Shcheglova IA. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bull Exp Biol Med. 2006;142(3):356-359. Paywalled. Concerns epithalamin, the gland extract, not epitalon. pubmed.ncbi.nlm.nih.gov/17426848
US Food and Drug Administration. Epitalon-related bulk drug substances (epitalon (free base) and epitalon acetate): FDA presentation to the Pharmacy Compounding Advisory Committee, 24 July 2026. Docket FDA-2025-N-6895. Primary source for the nomination, the effectiveness and safety findings, the telomere concern, the 2018 prosecution and the FDA's recommendation. fda.gov
McNally EJ, Luncsford PJ, Armanios M. Long telomeres and cancer risk: the price of cellular immortality. J Clin Invest. 2019;129(9):3474-3481. Open access. pubmed.ncbi.nlm.nih.gov/31380804
ONPEPS. FDA peptide news July 2026: the only source you need. Records the 7 to 4 vote with one abstention on epitalon. onpeps.com
Anisimov VN, Khavinson VKh, Alimova IN, Semchenko AV, Yashin AI. Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice. Bull Exp Biol Med. 2002;134(2):187-190. Paywalled. pubmed.ncbi.nlm.nih.gov/12459848
Kossoy G, Anisimov VN, Ben-Hur H, Kossoy N, Zusman I. Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis in female C3H/He mice. In Vivo. 2006;20(2):253-257. Open access. pubmed.ncbi.nlm.nih.gov/16634527
US Food and Drug Administration. Category 2 of the Bulk Substances Nominated Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Entry for epitalon. Content current as of 22 April 2026. fda.gov

Not Medical Advice

Epitalon is not approved for human use in any jurisdiction, has no human safety data by any route, and works, if it works, through a mechanism that regulators identify as a cancer concern. Consult a qualified healthcare provider before acting on anything here.

Evidence counts on the library index retrieved 23 July 2026. Literature and regulatory sources verified 16 September 2026. The FDA had not acted on the July 2026 advisory recommendation as of that date. Re-verify against docket FDA-2025-N-6895 before relying on any regulatory statement here.

Epitalon